계명대학교 의학도서관 Repository

Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients

Metadata Downloads
Author(s)
Hyery KimHyoung Jin KangKyung Duk ParkKyung-Nam KohHo Joon ImJong Jin SeoJae Wook LeeNack-Gyun ChungBin ChoHack Ki KimJae Min LeeJeong Ok HahJun Ah LeeYoung Ho LeeSang Kyu ParkHee Jo BaekHoon KookJi Yoon KimHeung Sik KimHwang Min KimHee Won ChuehMeerim ParkHoi Soo YoonMee Jeong LeeHyoung Soo ChoiHyo Seop AhnYoshifumi KawanoJi Won ParkSeokyung HahnHee Young Shin
Keimyung Author(s)
Kim, Ji YoonKim, Heung Sik
Department
Dept. of Pediatrics (소아청소년학)
Journal Title
Cancer Research and Treatment
Issued Date
2019
Volume
51
Issue
1
Keyword
DexrazoxaneChildhoodCancerAnthracyclinesRisk factorsSecond neoplasm
Abstract
Purpose
Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients.

Materials and Methods
Data was collected from 15 hospitals in Korea. Patients who received any anthracyclines, and completed treatment without stem cell transplantation were included. For efficacy evaluation, the incidence of cardiac events and cardiac event-free survival rates were compared. Data about risk factors of secondary malignancies were collected.

Results
Data of total 1,453 cases were analyzed; dexrazoxane with every anthracyclines group (D group, 1,035 patients) and no dexrazoxane group (non-D group, 418 patients). Incidence of the reported cardiac events was not statistically different between two groups; however, the cardiac event-free survival rate of patients with more than 400 mg/m2 of anthracyclines was significantly higher in D group (91.2% vs. 80.1%, p=0.04). The 6-year cumulative incidence of secondary malignancy was not different between both groups after considering follow-up duration difference (non-D, 0.52%±0.37%; D, 0.60%±0.28%; p=0.55). The most influential risk factor for secondary malignancy was the duration of anthracycline administration according to multivariate analysis.

Conclusion
Dexrazoxane had an efficacy in lowering cardiac event-free survival rates in patients with higher cumulative anthracyclines. As a result of multivariate analysis for assessing risk factors of secondary malignancy, the occurrence of secondary malignancy was not related to dexrazoxane administration.
Keimyung Author(s)(Kor)
김지윤
김흥식
Publisher
School of Medicine (의과대학)
Citation
Hyery Kim et al. (2019). Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients. Cancer Research and Treatment, 51(1), 357–367. doi: 10.4143/crt.2017.457
Type
Article
ISSN
2005-9256
Source
https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2017.457
DOI
10.4143/crt.2017.457
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/41888
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Pediatrics (소아청소년학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.